WATCH LIVE IN
In response to the COVID-19 pandemic, our team will be interviewing experts from across the ecosystem to bring the HLTH community timely facts and updates. About Richard Saynor: Richard Saynor is Chief Executive Officer (CEO) for Sandoz, a global leader in generic and biosimilar medicines. Mr. Saynor has more than 20 years of pharmaceutical leadership experience in branded and generic medicines across established and emerging markets. He leads with the purpose to pioneer access for patients, and is committed to developing and commercializing high quality, affordable medicines that address unmet medical need. Richard Saynor joined Novartis from GlaxoSmithKline (GSK) Pte. Ltd., where he spent nine years in a variety of leadership roles across therapeutic areas and geographies. He most recently served as senior vice president of classic and established products as well as commercial and digital platforms. He was responsible for £10bn of post-patent products covering a number therapy areas (respiratory, allergy, urology, anti-infectives, CNS). Previously he held the roles of senior vice president and global head of established products and senior vice president of classic brands and generics for Europe, Japan, and the emerging markets and Asia-Pacific (EMAP) region. Prior to that, Richard Saynor held commercial operations leadership roles at Sandoz, serving as Region Head of Asian Markets, and as Region Head of Asia-Pacific, Latin America, Canada and Turkey. Richard Saynor earned his Bachelor of Pharmacy from the University of Bradford in the United Kingdom. He is a member of the Royal Pharmaceutical Society in the UK, and served on the board of GSK India from 2018 to 2019. However, he will tell you that his most important role is that of husband and dad.